Clinical Trial Update: Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein [Phase 1]

View source ↗

Summary

Phase 1 proof-of-mechanism study to evaluate binding of Alfa-synuclein has completed, involving Parkinson's disease and multiple system atrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy
• Parkinson Disease

Snippet

Sponsor: Invicro | Conditions: Parkinson Disease, Multisystem Atrophy | Phase 1 | Status: COMPLETED